hENT1 as a Predictive Biomarker in PDAC-Response

Sheron Perera; Gun Ho Jang; Robert Grant; Faiyaz Notta; Barbara Grunwald; Steven Gallinger; Jennifer J Knox; Grainne M O'Kane

doi:10.1158/1078-0432.CCR-23-0887

hENT1 as a Predictive Biomarker in PDAC-Response

Clin Cancer Res. 2023 Aug 1;29(15):2945-2948. doi: 10.1158/1078-0432.CCR-23-0887.

Authors

Sheron Perera^{1

2}, Gun Ho Jang³, Robert Grant^{1

3

4}, Faiyaz Notta^{1

3}, Barbara Grunwald^{4

5}, Steven Gallinger^{1

3

4}, Jennifer J Knox^{1

3

4}, Grainne M O'Kane^{1

3

4

6}

Affiliations

¹ University of Toronto, Toronto, Ontario.
² Odette Cancer Centre, Sunnybrook Health Science Centre, Toronto, Ontario.
³ Ontario Institute for Cancer Research, Toronto, Ontario.
⁴ Wallace McCain Centre for Pancreatic Cancer, Princess Margaret Cancer Center, University Health Network, Toronto, Ontario.
⁵ Department of Urology, West German Cancer Center, University Hospital Essen, Essen, Germany.
⁶ Trinity St. James's Cancer Institute, Dublin, Ireland.

PMID: 37525960
DOI: 10.1158/1078-0432.CCR-23-0887

No abstract available

MeSH terms

Biomarkers
Deoxycytidine
Equilibrative Nucleoside Transporter 1
Gemcitabine*
Humans
Pancreatic Neoplasms* / diagnosis
Pancreatic Neoplasms* / genetics

Substances

Gemcitabine
Deoxycytidine
Biomarkers
Equilibrative Nucleoside Transporter 1